The outlook for patients with malignant mesothelioma of the pleura is generally extremely poor, with median survival rates around 12 months or less . Local treatment with surgery, radiotherapy or systemic chemotherapy has so far been unsuccessful in improving this situation (Brenner et al., 1982) . However, some reports on small numbers of patients indicate that some cytotoxic drugs may be active (Aisner and Wiernik, 1981; Falkson et al., 1988) . Methotrexate has been regarded as one of these agents, especially when given in escalated doses (Dimitrov et al., 1982) . The number of patients treated has however been too small for definite confirmation of activity or inactivity. This report addresses the results of high-dose methotrexate (HDMTX) treatment in a relative large series of patients.
Material and methods

Patients
Following the initial report of Dimitrov et al. (1982) on HDMTX therapy of malignant mesothelioma, a phase II trial was initiated in our institution to study the effect of chemotherapy with HDMTX in this disease. From 1984 to 1989, a total of 73 patients with malignant pleural mesothelioma were admitted to our institution; 70 male and three female. Their age distribution is shown in Figure 1 . Median age at diagnosis was 60 years (range 39-76 years). Fifty-nine patients (81%) reported some degree of previous exposure to asbestos, and 54% had been repeatedly exposed in their occupation for prolonged periods of time (Table I) .
Patients were eligible for the HDMTX study if they had histologically proven malignant mesothelioma of the pleura, symptomatic disease in need of palliative treatment, Karnofsky index > 50, no evidence of mestastases to the central nervous system, and normal renal function as judged by serum creatinine. Of the 73 patients admitted during the study period, eight patients were excluded due to a Karnofsky index < 50, and one patient with very slowly progressing disease and minimal symptoms was treated by irradiation of an implantation metastasis only. HDMTX treatment was~2 Computerised tomography Computerised tomography of the chest and upper abdomen was performed before start of treatment. The thickness of the sections was 5 mm and the spacing 10 mm. As contrast medium, 50 ml Iohexol 300 mg ml ' was injected as bolus followed by infusion of 200 ml lohexol 140 mg ml-'.
For evaluation of response, the examination was repeated 3 weeks after the fourth methotrexate infusion and, for patients continuing treatment, 3 weeks after the eighth infusion. For each patient every CT image was compared with the corresponding image from the previous examination. To ensure identical localisation of CT images, anatomical landmarks in vertebrae, ribs or the central bronchial tree were used during the CT scanning procedure. The thickness of the tumourous parietal, visceral, diaphragmatic, and mediastinal pleura was measured together with any enlarged lymph nodes in the mediastinum, rectrocural space or axillae. Care was taken to distinguish tumour from organised pleural fluid and lung atlectasis. Accumulation of contrast medium was used to aid the distinction between tumour and benign pleural thickening.
The staging system This was similar to that proposed by Butchart et al. (1976) Treatment response The growth pattern of pleural mesothelioma is diffuse, and the tumour often invades most or all of the pleural surface of one hemithorax. CT scans of such a patient are shown in Figure 2 . Conventional WHO criteria for tumour measurement and response evaluation, requiring the identification of two perpendicular tumour diameters, are unsuitable for the evaluation of tumour 'size' in this disease. If these criteria were to be employed in mesothelioma, the majority of patients would be ineligible for the study of treatment response, and reported results would represent only a small, highly selected group of patients. We are not aware of any recommended alternative system for response evaluation suitable for malignant mesothelioma.
Multiple studies have concluded that CT scanning is the method of choice for tumour evaluation in this disease, as reviewed by Whitley (1987) . The superiority of CT scan over conventional chest X-ray is also clearly evident from Figure  2 . Thus, in the present study, tumour response was evaluated by CT scans according to the following definitions:
Progressive disease: Increase of tumour thickness in three sections by 30% or more, or in two sections by 50% or more. Appearance of regional (usually mediastinal) or distant metastases.
Partial remission: Corresponding decrease in tumour thickness (as illustrated in Figure 2 ), without appearance of regional or distant metastases. Changes in the amount of pleural fluid present were not included in the response evaluation, and care was taken not to interpret reduced atelectasis after pleural drainage as tumour shrinkage. 
Treatment
Before the methotrexate infusion, prehydration with 200 ml NaHCO3 (500 mmol 1') in 300 ml-NaCl was given over 30 min. Methotrexate was administered as a 16 h infusion with a standard dose of 3 g in 1,000 ml NaHCO3. All HDMTX courses in this study were given with this dose, without dose modifications. Hydration was carried out with a minimal fluid intake of 2,500mlm-2 day-' and a minimal fluid output of 2,000mlm-2 day-'. For urine alkalinisation 3 g NaHCO3 was given every 6 h, and with increased doses if urinary pH fell below 7.0. Citrovorum factor (CF) rescue was initiated 24 h after start of MTX infusion with 15 mg every 6 h, until the serum MTX concentration fell below 80 nmol 1-1 (0.8 x 10-7 M), after which the patients were discharged from hospital. The number of CF doses were adjusted according to the serum MTX concentration, and the minimum number of CF doses was 11.
The first four infusions were given with 10 day intervals. Response was evaluated 3 weeks later. Patients showing response (or no change, but with subjective improvement), continued treatment with four additional infusions, administered with 21 day intervals.
In the later course of the disease some patients were treated with additional HDMTX, weekly doxorubicin or by palliative irradiation.
Results
All patients were symptomatic (shortness of breath and/or pain). The onset of these symptoms were usually gradual and could not be defined accurately. (Dahl & Laurent, 1988 , Dahl et al., 1989 , were found in 28 of the 50 patients studied (56%). Substantially elevated levels of hyaluronate were found in the pleural fluid in all 13 cases studied.
Tumour response Three patients were. not evaluable for tumour response. One of these suffered a toxic death during the second HDMTX course, one patient had only one HDMTX course due to toxicity, and one patient was withdrawn from further HDMTX therapy after only one course (by his local hospital), and was subsequently lost to follow-up. Of the remaining 60 patients, 37% showed objective tumour response, 32% showed no change, and 32% showed progressive disease (Table IV) . Median response duration was 7.5 months (range 4-70 + months), and median duration of stable disease was 10 months (range 2-31 + months). Pleural fluid and pain were commonly reduced, also in patients showing no change in tumour size. There was no evidence of differences in response rates between the different histological subtypes, and the response rate was not correlated to the extent of disease by Butchart staging. However, the numbers of patients in the different sub-groups were too small for such comparisons.
Survival
The actuarial survival for all 63 patients is shown in Figure  3 . Fifty-four patients have died during the study period, median observation time for the nine patients still alive was 37 months (range 17-70 months). Median survival for all patients was 11 months, with patients with the epithelial type doing significantly better (median survival 12 months) than patients with mixed or pure sarcomatous types (5 months, P = 0.001, log-rank test). After 2 years, 32% of the patients with the epithelial type were alive. In contrast, only one patient (5%) with the sarcomatous/mixed type was alive after 2 years.
Toxicity
In 27 of the patients (42%), no toxicity was recorded. In 27 others, low-grade toxicity in the form of mild nausea, stomatitis or conjunctivitis was noted, these episodes did not interfere with the treatment plan.
Delayed MTX excretion was observed in six patients (9%).
In these cases, serum MTX concentrations reached 80 nmol 1' after 9, 8, 6, 5, 5 and 5 days respectively. The delay occurred after the first MTX infusion in three patients, and after the third to seventh infusion in the other three. The incidents led to termination of MTX treatment for five of these six patients. No evidence was found suggesting that pleural fluid acting as a 'third compartment' contributed to delayed MTX excretion. These incidents were generally correlated with moderate and transient rises in serum creatinine, pointing to a pre-treatment reduction in renal function or direct renal MTX toxicity as the most likely causes of delayed MTX clearance. One patient developed an allergic/toxic reaction which started on the second day after his first MTX infusion, with a generalised exanthema and an increase in serum creatinine. On the third day pneumonitis became evident. The excretion of MTX was not delayed, and the symptoms disappeared gradually. Subsequently, seven HDMTX courses were administered without complications.
One toxic death occurred. This was a 60 year old man with stage III disease, who developed exanthema and pneumonitis 5 h after start of his second MTX infusion. The infusion was immediately stopped. Fever appeared on the second day. Complete bone marrow failure ensued, and the serum creatinine level increased steadily until death on the sixth day.
Post mortem examination showed tumour infiltration in the chest wall, pericardium and mediastinum, and the bone marrow was aplastic.
Discussion
In our series of patients the distribution of age, asbestos exposure, histological type, and stage are similar to that in most other reports Antman et al., 1988) , making it unlikely that the selection of patients in this material has been biased with regard to chemosensitivity.
In 1982, Dimitrov et al. reported the effects of HDMTX in nine patients with malignant mesothelioma. Of six patients with pleural disease, three showed complete remission and two showed partial response. Although these results are often quoted in the more recent literature Talcott & Antman, 1988) , we are not aware of any other reports on HDMTX therapy of malignant mesothelioma.
Due to the diffuse growth of pattern of pleural mesothelioma, the tumour extension is difficult to evaluate according to classical WHO criteria. We therefore chose to apply tumour thickness as measured by CT scanning as our response parameter, this providing a specific tumour measurement. In most other reports, the method employed for tumour measurement is poorly documented (Colbert et al., 1985; Mintzen et al., 1985; Raghavan et al., 1990; Sorensen et al., 1985) . This makes it difficult to directly compare our results with those of others, and it is equally difficult to compare the results of previous studies with each other. The main intention of the present study was thus to investigate whether or not HDMTX is an active regimen in malignant mesothelioma, rather than to compare its activity with that of previously tested agents. Due to the difficulty in response evaluation in mesothelioma, the effect of treatment on subsequent survival is of particular importance. Median survival in the present series is comparable to that reported in several other series Antman et al., 1988; Brenner et al., 1982) , i.e. 11 months for the group as a whole, 12 months for patients with epithelial type, and only 5 months for patients with sarcomatous or mixed types (Figure 3) . Some epithelial mesotheliomas are known to have a slow natural growth rate. Studies of untreated patients have thus shown prolonged survival for 10-15% of patients (Law et al., 1984) . A slow natural growth rate may also explain why, in our study, stable disease on average lasted longer (median 10 months) than the objective responses (7.5 months). Thirty-two per cent of the patients with the epithelial type survived for more than 2 years, and 18% survived for more than 3 years. This may suggest a possible effect of HDMTX on survival in this histological subgroup. Due to disease progression following HDMTX treatment, 18 patients were subsequently treated with doxorubicin, and nine were treated with palliative radiotherapy. Whether this therapy may have contributed to improved survival remains unknown.
Despite the high age of most patients and the presence of significant amounts of pleural fluid, the treatment with HDMTX did not result in unacceptable toxicity. However, we emphasise that the chemotherapy protocol was followed meticulously, and that the patients were monitored carefully during the MTX excretion phase.
In conclusion, high dose methotrexate is an active regimen in the treatment of patients with diffuse malignant mesothelioma of the pleura, as shown by an objective response rate of 37%. With careful monitoring of the patients, the treatment is safe for patients less than 80 years old in fair condition. patients with sarcomatous or mixed histological subtypes, the treatment should possibly be reserved for patients with the epithelial type of mesothelioma. However, this finding needs verification in a larger number of patients. It should also be emphasised that the response rate reported in this series should be interpreted with caution, as mesothelioma is a difficult disease to evaluate, necessitating novel methods for tumour measurement. Randomised studies are required to establish whether HDMTX treatment can improve survival for these patients. Considering the cost of HDMTX therapy, the demonstration of a survival benefit seems necessary for the justification of HDMTX as routine treatment for mesothelioma. Finally, the optimal dosage and treatment duration also remain to be established.
